Abstract | OBJECTIVE: DATA SOURCES: DATA SYNTHESIS:
Heart failure is widely prevalent and continues to be associated with high morbidity and mortality, even with currently recommended care. At the moderate doses studied for patients with mild heart failure in brief trials, combined ACE inhibitor and ARB therapy was well tolerated and had an additive effect in reducing blood pressure and relieving symptoms of heart failure. CONCLUSIONS: An ARB combined with an ACE inhibitor may benefit heart failure patients who are receiving all other recommended therapies. Further trials are needed to evaluate long-term safety effectiveness, quality of life, and survival before the combination can be recommended for routine use.
|
Authors | D R Struckman, M P Rivey |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 35
Issue 2
Pg. 242-8
(Feb 2001)
ISSN: 1060-0280 [Print] United States |
PMID | 11215846
(Publication Type: Journal Article, Review)
|
Chemical References |
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin II
|
Topics |
- Angiotensin II
(metabolism)
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Animals
- Drug Therapy, Combination
- Heart Failure
(drug therapy)
- Humans
|